230 related articles for article (PubMed ID: 30990729)
1. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.
Bustoros M; Sklavenitis-Pistofidis R; Kapoor P; Liu CJ; Kastritis E; Zanwar S; Fell G; Abeykoon JP; Hornburg K; Neuse CJ; Marinac CR; Liu D; Soiffer J; Gavriatopoulou M; Boehner C; Cappuccio JM; Dumke H; Reyes K; Soiffer RJ; Kyle RA; Treon SP; Castillo JJ; Dimopoulos MA; Ansell SM; Trippa L; Ghobrial IM
J Clin Oncol; 2019 Jun; 37(16):1403-1411. PubMed ID: 30990729
[TBL] [Abstract][Full Text] [Related]
2. Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.
Zanwar S; Abeykoon JP; Ansell SM; Gertz MA; Colby C; Larson D; Paludo J; He R; Warsame R; Greipp PT; King RL; Thompson CA; Witzig TE; Lacy MQ; Gonsalves W; Nowakowski GS; Dingli D; Go RS; Habermann TM; Vincent Rajkumar S; Kyle RA; Kumar S; Kapoor P
Br J Haematol; 2021 Oct; 195(2):210-216. PubMed ID: 34340248
[TBL] [Abstract][Full Text] [Related]
3. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ; Gustine J; Castillo JJ; Matous J; Ghobrial IM
Clin Cancer Res; 2017 May; 23(10):2400-2404. PubMed ID: 27836860
[No Abstract] [Full Text] [Related]
4. Asymptomatic Waldenstrom's macroglobulinemia.
Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
[TBL] [Abstract][Full Text] [Related]
5. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
6. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840
[TBL] [Abstract][Full Text] [Related]
7. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.
Kyle RA; Therneau TM; Dispenzieri A; Kumar S; Benson JT; Larson DR; Melton LJ; Rajkumar SV
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):184-6. PubMed ID: 23490989
[TBL] [Abstract][Full Text] [Related]
9. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Rivkin SE; Roodman GD; Tuscano JM; Shurafa M; Kyle RA; Crowley JJ; Barlogie B
Blood; 2001 Jul; 98(1):41-8. PubMed ID: 11418461
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].
Tao Y; Wang S; Wang L; Wu M; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):993-997. PubMed ID: 35045669
[No Abstract] [Full Text] [Related]
12. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
[TBL] [Abstract][Full Text] [Related]
13. Highly sensitive
Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
[TBL] [Abstract][Full Text] [Related]
14. How I treat Waldenström macroglobulinemia.
Dimopoulos MA; Kastritis E
Blood; 2019 Dec; 134(23):2022-2035. PubMed ID: 31527073
[TBL] [Abstract][Full Text] [Related]
15. Waldenström macroglobulinemia treatment algorithm 2018.
Gertz MA
Blood Cancer J; 2018 May; 8(4):40. PubMed ID: 29712895
[TBL] [Abstract][Full Text] [Related]
16. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.
García-Sanz R; Dogliotti I; Zaccaria GM; Ocio EM; Rubio A; Murillo I; Escalante F; Aguilera C; García-Mateo A; García de Coca A; Hernández R; Dávila J; Puig N; García-Álvarez M; Chillón MDC; Alcoceba M; Medina A; González de la Calle V; Sarasquete ME; González M; Gutiérrez NC; Jiménez C
Br J Haematol; 2021 Mar; 192(5):843-852. PubMed ID: 32780894
[TBL] [Abstract][Full Text] [Related]
17. Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia.
Merli M; Bianchi B; Bertù L; Ferrario A; Mora B; Furlan D; Uccella S; Sessa F; Passamonti F
Leuk Lymphoma; 2020 Apr; 61(4):987-989. PubMed ID: 31724890
[No Abstract] [Full Text] [Related]
18. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
[TBL] [Abstract][Full Text] [Related]
19. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
[TBL] [Abstract][Full Text] [Related]
20. Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia.
Cho JH; Shim JH; Yoon SE; Kim HJ; Kim SH; Ko YH; Lee ST; Kim K; Kim WS; Kim SJ
Korean J Intern Med; 2021 May; 36(3):668-678. PubMed ID: 32791817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
